29 August 2022 - Formycon, Polpharma Biologics and Bioeq jointly announce that the European Commission has granted marketing authorisation for Ranivisio (ranibizumab), a biosimilar to Lucentis (ranibizumab), for the treatment for several serious retinal diseases in the European Union.

The EU approval is based on the totality of evidence including analytical, non-clinical, clinical and manufacturing data.

Read Formycon press release